Meningococcal B Vaccine Recommendation

Lafene Health Center will follow the recommendations of the Advisory Committee on Immunization Practices, a branch of the CDC, re. patient selection for administration of the Serogroup B Meningococcal Vaccine. These recommendations are as follows:

“Certain persons aged more than or equal 10 years who are at increased risk for meningococcal disease should receive MenB vaccine.” These persons include:

a) Persons with persistent complement component deficiencies.
b) Persons without a spleen (asplenia.)
c) Persons identified as at increased risk because of a serogroup B meningococcal disease outbreak.

Students who do not have either of the above disorders in a) or b) and wish to receive this vaccine should consult their primary care provider for his/her advice. Lafene will have some Meningococcal B vaccine in stock for use if indicated and approved by the Medical Director. *This vaccine is NOT required for University Housing residents @ K-State.*

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6422a3.htm